ArticleBiomarker insights2021
Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms.
Article in Biomarker insights, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.JCI insight · 2021Trial
- Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients.Biomedicines · 2026Article
- Comparative evaluation of performance and precision of multiplex immunoassays measuring human IgG toFrontiers in immunology · 2026Article
- Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial.Neuro-oncology · 2025Article
- Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.Journal of advanced research · 2025Review
- Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology.Molecular & cellular proteomics : MCP · 2024Review
- The role of IL-17 in the pathogenesis and treatment of glioblastoma-an update on the state of the art and future perspectives.Medical oncology (Northwood, London, England) · 2024Review
- Cytokine Profile in Development of Glioblastoma in Relation to Healthy Individuals.International journal of molecular sciences · 2023Article
- Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential.Cells · 2023Review
- Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.Clinical and translational science · 2022Article
- Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volunteers (n = 11). Assays included a bead-based fluorescence MILLIPLEX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.